This is part 4 of an interview. Watch part 1, part 2, and part 3.

Chromosome 13q linkage promotes RB1 hemizygosity during BRCA2 LOH, lowering the ‘two-hit’ barrier and predisposing to ...

New KRAS-targeting drug for metastatic pancreatic cancer nearly doubles second-line survival; expert explains impact, side ...

MCED screening and broader genetic testing push community oncology toward prevention—learn how practices adapt workflows, training, and follow-up for high-risk patients.

Joseph Mikhael, MD, MEd, discusses the potential and limitations of at-home cancer care using on-body injection technology.

Betts, MD, discusses how PTCy and tacrolimus protocols, as well as using younger donors, contributes to higher survival rates ...

AI-built social posts aim to raise young women’s awareness that alcohol increases breast cancer risk, while a trial tracks ...

Dr Joyce Ohm discusses the ethical questions raised by genome sequencing, from data ownership to reporting mutations of unknown significance. This is part 3 of an interview. Watch part 1 and part 2.

In an interview with Targeted OncologyTM, Ranjit Goudar, MD, of Virginia Oncology Associates, discusses the ongoing barriers to genetic testing and hereditary cancer risk assessment, emphasizing that ...

Betts, MD, discusses how discharging patients as early as day 5 after stem cell transplant has proved feasible and improves ...

A Big Ten Cancer Research Consortium project is testing counter-marketing, plain-language messages tailored for social media to increase alcohol–breast cancer risk awareness. AI-built social posts aim ...

Community oncology expands hereditary cancer genetic testing with team-based counseling, trained clinicians, and structured follow-up pathways for complex results and high-risk families.